Supreme Court Directs Centre to Form Panel on Pharma Marketing Practices
Why in the news
On 8 October 2026, the Supreme Court directed the Centre to constitute a three-member committee to study whether the marketing practices of pharmaceutical companies should be brought under a statutory framework.
Key facts
- Bench: Justices Vikram Nath and Sandeep Mehta.
- Three-member committee: to examine whether pharma marketing, including gifts and other benefits given to doctors, requires statutory regulation.
- Mandate: consider the views of stakeholders and recommend whether a statutory framework is needed and, if so, what shape it should take.
- Regulatory gap: the court observed that the present system allows action against doctors who accept such benefits, but has no equivalent statutory mechanism against the companies that offer them.
- Compliance: the Centre has to file an affidavit on compliance; the case is listed next on 29 January.
- Context: the issue arose alongside the court’s separate review of medicine pricing and affordability, including a reported ten-fold gap between the retailer price and MRP of a cancer medicine.
At a glance
| Item | Detail |
|---|---|
| Date of order | 8 October 2026 |
| Committee size | Three members |
| Next hearing | 29 January |
About the issue
The plea before the court sought action against unethical interactions between drug companies and doctors. Inducements such as gifts can influence prescribing and raise the cost of treatment for patients, which is why the court wants a study on regulating the companies’ side of the relationship.
Exam angle
- Note the bench: Justices Vikram Nath and Sandeep Mehta.
- Key gap: doctors are covered by rules, pharma companies lack an equivalent statutory mechanism.
- Links to health governance and drug pricing topics.